ArticleRadiology2019
Interreader Variability of Dynamic Contrast-enhanced MRI of Recurrent Glioblastoma: The Multicenter ACRIN 6677/RTOG 0625 Study.
Abstract read
In one paragraph
Article in Radiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Comparison of gadobutrol and meglumine gadoterate for dynamic contrast-enhanced MRI of pituitary macroadenomas.Scientific reports · 2025Trial
- Radiomics in glioblastoma recurrence: advances in prediction, localization, and differentiation from treatment-related effects.Journal of translational medicine · 2026Review
- Preoperative FLAIR images for identifying glioblastoma boundaries.BMC medical imaging · 2025Article
- Multi-contrast 4DMR via MR multitasking: Early clinical experience and implication for liver stereotactic body radiation therapy.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2025Article
- Biopsy location and tumor-associated macrophages in predicting malignant glioma recurrence using an in-silico model.NPJ systems biology and applications · 2025Article
- Noninvasive MGMT-promotor methylation prediction in high grade gliomas using conventional MRI and deep learning-based segmentations.Frontiers in neuroscience · 2025Article
- Deep learning-based super-resolution and denoising algorithm improves reliability of dynamic contrast-enhanced MRI in diffuse glioma.Scientific reports · 2024Article
- Advanced magnetic resonance imaging for glioblastoma: Oncology-radiology integration.Surgical neurology international · 2024Article
- Development and validation of a MRI-radiomics-based machine learning approach in High Grade Glioma to detect early recurrence.Frontiers in oncology · 2024Article
- Reliability of dynamic susceptibility contrast perfusion metrics in pre- and post-treatment glioma.Cancer imaging : the official publication of the International Cancer Imaging Society · 2022Article
- Advanced MRI Protocols to Discriminate Glioma From Treatment Effects: State of the Art and Future Directions.Frontiers in radiology · 2022Review
- Article
- Evaluation of Multisource Adaptive MRI Fusion for Gross Tumor Volume Delineation of Hepatocellular Carcinoma.Frontiers in oncology · 2022Article
- Multi-contrast four-dimensional magnetic resonance imaging (MC-4D-MRI): Development and initial evaluation in liver tumor patients.Medical physics · 2021Article
- Diffusion and perfusion MRI radiomics obtained from deep learning segmentation provides reproducible and comparable diagnostic model to human in post-treatment glioblastoma.European radiology · 2021Article
- Preoperative Magnetic Resonance Imaging Radiomics for Predicting Early Recurrence of Glioblastoma.Frontiers in oncology · 2021Article
- Automatic assessment of glioma burden: a deep learning algorithm for fully automated volumetric and bidimensional measurement.Neuro-oncology · 2019Article
- Repeatability of tumor perfusion kinetics from dynamic contrast-enhanced MRI in glioblastoma.Neuro-oncology advancesArticle
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Daniel P BarboriakFrom the Department of Radiology, Duke University Medical Center, 2301 Erwin Rd, Durham, NC 27710 (D.P.B.); Department of Biostatistics and Center for Statistical Sciences, Brown University, Providence, RI (Z.Z.); Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center, Houston, Tex (P.D.); Center for Statistical Sciences, Brown University School of Public Health, Providence, RI (B.S.S.); Pharmascan Clinical Trials and Radiology Associates of Clearwater, University of South Florida, Clearwater, Fla (Y.S.); Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, Mo (R.C.M.); Neuro-Oncology Service, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel (F.B.); A.A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, Mass (G.S.); Siemens Healthcare, Malvern, Pa (G.S.); Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Tex (M.R.G.); and Department of Diagnostic Imaging, Rhode Island Hospital and Alpert Medical School of Brown University, Providence, RI (J.L.B.).ORCID 0000-0002-2536-6266
Zheng ZhangFrom the Department of Radiology, Duke University Medical Center, 2301 Erwin Rd, Durham, NC 27710 (D.P.B.); Department of Biostatistics and Center for Statistical Sciences, Brown University, Providence, RI (Z.Z.); Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center, Houston, Tex (P.D.); Center for Statistical Sciences, Brown University School of Public Health, Providence, RI (B.S.S.); Pharmascan Clinical Trials and Radiology Associates of Clearwater, University of South Florida, Clearwater, Fla (Y.S.); Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, Mo (R.C.M.); Neuro-Oncology Service, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel (F.B.); A.A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, Mass (G.S.); Siemens Healthcare, Malvern, Pa (G.S.); Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Tex (M.R.G.); and Department of Diagnostic Imaging, Rhode Island Hospital and Alpert Medical School of Brown University, Providence, RI (J.L.B.).
Pratikkumar DesaiFrom the Department of Radiology, Duke University Medical Center, 2301 Erwin Rd, Durham, NC 27710 (D.P.B.); Department of Biostatistics and Center for Statistical Sciences, Brown University, Providence, RI (Z.Z.); Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center, Houston, Tex (P.D.); Center for Statistical Sciences, Brown University School of Public Health, Providence, RI (B.S.S.); Pharmascan Clinical Trials and Radiology Associates of Clearwater, University of South Florida, Clearwater, Fla (Y.S.); Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, Mo (R.C.M.); Neuro-Oncology Service, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel (F.B.); A.A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, Mass (G.S.); Siemens Healthcare, Malvern, Pa (G.S.); Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Tex (M.R.G.); and Department of Diagnostic Imaging, Rhode Island Hospital and Alpert Medical School of Brown University, Providence, RI (J.L.B.).
Bradley S SnyderFrom the Department of Radiology, Duke University Medical Center, 2301 Erwin Rd, Durham, NC 27710 (D.P.B.); Department of Biostatistics and Center for Statistical Sciences, Brown University, Providence, RI (Z.Z.); Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center, Houston, Tex (P.D.); Center for Statistical Sciences, Brown University School of Public Health, Providence, RI (B.S.S.); Pharmascan Clinical Trials and Radiology Associates of Clearwater, University of South Florida, Clearwater, Fla (Y.S.); Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, Mo (R.C.M.); Neuro-Oncology Service, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel (F.B.); A.A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, Mass (G.S.); Siemens Healthcare, Malvern, Pa (G.S.); Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Tex (M.R.G.); and Department of Diagnostic Imaging, Rhode Island Hospital and Alpert Medical School of Brown University, Providence, RI (J.L.B.).
Yair SafrielFrom the Department of Radiology, Duke University Medical Center, 2301 Erwin Rd, Durham, NC 27710 (D.P.B.); Department of Biostatistics and Center for Statistical Sciences, Brown University, Providence, RI (Z.Z.); Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center, Houston, Tex (P.D.); Center for Statistical Sciences, Brown University School of Public Health, Providence, RI (B.S.S.); Pharmascan Clinical Trials and Radiology Associates of Clearwater, University of South Florida, Clearwater, Fla (Y.S.); Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, Mo (R.C.M.); Neuro-Oncology Service, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel (F.B.); A.A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, Mass (G.S.); Siemens Healthcare, Malvern, Pa (G.S.); Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Tex (M.R.G.); and Department of Diagnostic Imaging, Rhode Island Hospital and Alpert Medical School of Brown University, Providence, RI (J.L.B.).
Robert C McKinstryFrom the Department of Radiology, Duke University Medical Center, 2301 Erwin Rd, Durham, NC 27710 (D.P.B.); Department of Biostatistics and Center for Statistical Sciences, Brown University, Providence, RI (Z.Z.); Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center, Houston, Tex (P.D.); Center for Statistical Sciences, Brown University School of Public Health, Providence, RI (B.S.S.); Pharmascan Clinical Trials and Radiology Associates of Clearwater, University of South Florida, Clearwater, Fla (Y.S.); Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, Mo (R.C.M.); Neuro-Oncology Service, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel (F.B.); A.A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, Mass (G.S.); Siemens Healthcare, Malvern, Pa (G.S.); Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Tex (M.R.G.); and Department of Diagnostic Imaging, Rhode Island Hospital and Alpert Medical School of Brown University, Providence, RI (J.L.B.).
Felix BoksteinFrom the Department of Radiology, Duke University Medical Center, 2301 Erwin Rd, Durham, NC 27710 (D.P.B.); Department of Biostatistics and Center for Statistical Sciences, Brown University, Providence, RI (Z.Z.); Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center, Houston, Tex (P.D.); Center for Statistical Sciences, Brown University School of Public Health, Providence, RI (B.S.S.); Pharmascan Clinical Trials and Radiology Associates of Clearwater, University of South Florida, Clearwater, Fla (Y.S.); Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, Mo (R.C.M.); Neuro-Oncology Service, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel (F.B.); A.A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, Mass (G.S.); Siemens Healthcare, Malvern, Pa (G.S.); Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Tex (M.R.G.); and Department of Diagnostic Imaging, Rhode Island Hospital and Alpert Medical School of Brown University, Providence, RI (J.L.B.).
Gregory SorensenFrom the Department of Radiology, Duke University Medical Center, 2301 Erwin Rd, Durham, NC 27710 (D.P.B.); Department of Biostatistics and Center for Statistical Sciences, Brown University, Providence, RI (Z.Z.); Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center, Houston, Tex (P.D.); Center for Statistical Sciences, Brown University School of Public Health, Providence, RI (B.S.S.); Pharmascan Clinical Trials and Radiology Associates of Clearwater, University of South Florida, Clearwater, Fla (Y.S.); Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, Mo (R.C.M.); Neuro-Oncology Service, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel (F.B.); A.A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, Mass (G.S.); Siemens Healthcare, Malvern, Pa (G.S.); Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Tex (M.R.G.); and Department of Diagnostic Imaging, Rhode Island Hospital and Alpert Medical School of Brown University, Providence, RI (J.L.B.).
Mark R GilbertFrom the Department of Radiology, Duke University Medical Center, 2301 Erwin Rd, Durham, NC 27710 (D.P.B.); Department of Biostatistics and Center for Statistical Sciences, Brown University, Providence, RI (Z.Z.); Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center, Houston, Tex (P.D.); Center for Statistical Sciences, Brown University School of Public Health, Providence, RI (B.S.S.); Pharmascan Clinical Trials and Radiology Associates of Clearwater, University of South Florida, Clearwater, Fla (Y.S.); Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, Mo (R.C.M.); Neuro-Oncology Service, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel (F.B.); A.A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, Mass (G.S.); Siemens Healthcare, Malvern, Pa (G.S.); Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Tex (M.R.G.); and Department of Diagnostic Imaging, Rhode Island Hospital and Alpert Medical School of Brown University, Providence, RI (J.L.B.).
Jerrold L BoxermanFrom the Department of Radiology, Duke University Medical Center, 2301 Erwin Rd, Durham, NC 27710 (D.P.B.); Department of Biostatistics and Center for Statistical Sciences, Brown University, Providence, RI (Z.Z.); Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center, Houston, Tex (P.D.); Center for Statistical Sciences, Brown University School of Public Health, Providence, RI (B.S.S.); Pharmascan Clinical Trials and Radiology Associates of Clearwater, University of South Florida, Clearwater, Fla (Y.S.); Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, Mo (R.C.M.); Neuro-Oncology Service, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel (F.B.); A.A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, Mass (G.S.); Siemens Healthcare, Malvern, Pa (G.S.); Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Tex (M.R.G.); and Department of Diagnostic Imaging, Rhode Island Hospital and Alpert Medical School of Brown University, Providence, RI (J.L.B.).
Funding
NRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8MARRA - ADOPT New Technologies for RDC/CDMSU01CA080098 · NCI · AMERICAN COLLEGE OF RADIOLOGY · PI SCHNALL, MITCHELL D. · 1999 to 2011
$182.7MWomen's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI DONNA NIEDZWIECKI · 1985 to 2026
$174.8MProject-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · 2014 to 2026
$167.6MRTOG Foreign AccrualU10CA021661 · NCI · AMERICAN COLLEGE OF RADIOLOGY · PI CURRAN, WALTER J. · 1985 to 2013
$150.3MStatistics CoreU10CA180822 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Mei-Yin C Polley · 2014 to 2026
$146.4MStatistics CoreU10CA180794 · NCI · DANA-FARBER CANCER INST · PI PAUL J CATALANO, CONSTANTINE A. GATSONIS · 2014 to 2026
$111.2MBIOSTATISTICS DATA MANAGEMENT CENTER FOR ACROINU01CA079778 · NCI · BROWN UNIVERSITY · PI GATSONIS, CONSTANTINE A. · 1999 to 2011
$48.6MBrain Tumor Clinical and Clinical Research Program (Clinical Support Services)ZIDBC011642 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI OZER, BYRAM · 2015 to 2025
$23.4MAmerican College of Radiology Imaging NetworkU10CA080098 · NCI · AMERICAN COLLEGE OF RADIOLOGY · PI SCHNALL, MITCHELL D. · 2012 to 2013
$9.4MBiostatistics Data Management Center for ACRINU10CA079778 · NCI · BROWN UNIVERSITY · PI GATSONIS, CONSTANTINE A. · 2013 to 2013
$2.4MNCI NIH HHS P30 CA014236NCI NIH HHS U01 CA079778NCI NIH HHS U01 CA080098NCI NIH HHS U10 CA021661NCI NIH HHS U10 CA079778NCI NIH HHS U10 CA080098NCI NIH HHS U10 CA180794NCI NIH HHS U10 CA180820NCI NIH HHS U10 CA180822NCI NIH HHS U10 CA180868
Abstract
Purpose To evaluate factors contributing to interreader variation (IRV) in parameters measured at dynamic contrast material-enhanced (DCE) MRI in patients with glioblastoma who were participating in a multicenter trial. Materials and Methods A total of 18 patients (mean age, 57 years ± 13 [standard deviation]; 10 men) who volunteered for the advanced imaging arm of ACRIN 6677, a substudy of the RTOG 0625 clinical trial for recurrent glioblastoma treatment, underwent analyzable DCE MRI at one of four centers. The 78 imaging studies were analyzed centrally to derive the volume transfer constant (K
Indexed as
AdultAgedBrain NeoplasmsFemaleGlioblastomaHumansMagnetic Resonance ImagingMaleMiddle AgedNeoplasm Recurrence, LocalObserver VariationRadiologistsYoung Adult
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.